SER Serina Therapeutics (SER) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001708599
Cluster · 4 insiders
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $19.5M priced
What the filings say about SER
Insiders, 180 days
+$78.0K net bought
4 buyers
Serina Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Serina Therapeutics, Inc. insiders bought a net $78.0K of stock across 78 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 1,000 shares held after it.
- 1 other insider bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Brannan Stephen K. bought about $2.0K of SER on Jul 7, 2026; 1 other insider bought within 30 days and 10 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jun 11, 2026.
- +42.0% median (+40.0% mean) 90-day return after 3 previous buys.
- The trade is 49.5% of the 10,100 shares held after it.
- 3 other insiders bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WILSON KAREN J bought about $8.8K of SER on Jun 12, 2026; 3 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 22, 2026.
- +39.0% median (+39.0% mean) 90-day return after 2 previous buys.
- The trade is 100.0% of the 5,100 shares held after it.
- 3 other insiders bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WILSON KAREN J bought about $8.9K of SER on Jun 11, 2026; 3 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 589 shares held after it.
- 2 other insiders bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Venkatesan Jay bought about $1.0K of SER on May 22, 2026; 2 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 21, 2026.
- The trade is 50.0% of the 20,000 shares held after it.
- 2 other insiders bought within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WILSON KAREN J bought about $19.3K of SER on May 22, 2026; 2 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.78 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$78.0K over 180 days
more than 75% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 82% of Pharma & Biotech
Revenue
+132.1% year over year
more than 87% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.5% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 86% of Pharma & Biotech
The situation: each line is one rule over one dataset
4 insiders independently bought a net $78.0K while the stock fell 16% over six months, with no planned sales queued.
What changed in the last 30 days
Oct 27Insider buying stopped: no purchases in 90 days after 7 in the prior 90
Why it matters
The absence is the signal: 7 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch SER
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-68.1%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SER: institutional holders (13F)
13F holdings, latest reported quarter
1,000,000 sh
$1.9M
162,198 sh
$314.7K
67,492 sh
$130.9K
51,007 sh
$99.0K
21,508 sh
$41.7K
Congress trades in SER
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SER planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SER mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$4.8K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$83.3K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$64.7K position · as of 2026-06-30
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$244.1K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$8.7K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$4.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $78.0K bought by insiders over 180 days, 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SER financials
Revenue growth
+132.1%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM SER
| FY Dec 2025 | $130.0K |
| FY Dec 2024 | $56.0K |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $34.0K |
| FY Dec 2021 | $144.0K |
| Jun 2026 | $0 |
| Mar 2026 | n/a |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $130.0K |
| Mar 2025 | $0 |
| Dec 2024 | -$14.0K |
| Sep 2024 | $14.0K |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM SER
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$21.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SER
| FY Dec 2025 | -$18.0M |
| FY Dec 2024 | -$17.2M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -$6.0M |
| FY Dec 2021 | -$7.9M |
| Jun 2026 | -$6.7M |
| Mar 2026 | -$4.6M |
| Dec 2025 | -$6.0M |
| Sep 2025 | -$3.9M |
| Jun 2025 | -$3.8M |
| Mar 2025 | -$4.3M |
| Dec 2024 | -$4.6M |
| Sep 2024 | -$3.0M |
At each fiscal year end
Single quarter
Debt to equity
0.16x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity SER
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.16x |
| Mar 2026 | 0.17x |
| Dec 2025 | n/a |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-6.85x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt SER
| FY Dec 2025 | -6.09x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -0.83x |
| FY Dec 2022 | -0.33x |
| FY Dec 2021 | -0.59x |
| Jun 2026 | -6.85x |
| Mar 2026 | -6.05x |
| Dec 2025 | -6.09x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -1.11x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-206.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SER
| FY Dec 2025 | -6,352% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -206.3% |
| Mar 2026 | -220.1% |
| Dec 2025 | -6,352% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-121.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SER
| FY Dec 2025 | -280.5% |
| FY Dec 2024 | -142.0% |
| FY Dec 2023 | +86.3% |
| FY Dec 2022 | -327.2% |
| FY Dec 2021 | -245.1% |
| Jun 2026 | -121.9% |
| Mar 2026 | -125.0% |
| Dec 2025 | -280.5% |
| Sep 2025 | -187.3% |
| Jun 2025 | -128.2% |
| Mar 2025 | -10.7% |
| Dec 2024 | -142.0% |
| Sep 2024 | -74.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital SER
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed SER
| FY Dec 2025 | -620.2% |
| FY Dec 2024 | -286.2% |
| FY Dec 2023 | -871.6% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | -189.6% |
| Dec 2025 | -620.2% |
| Sep 2025 | n/a |
| Jun 2025 | -1,290% |
| Mar 2025 | -3,501% |
| Dec 2024 | -286.2% |
| Sep 2024 | -769.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SER
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 19.64x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$22.0M
market value at close 2026-10-23 on 2026-08-10 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value SER
| FY Dec 2025 | $20.3M |
| FY Dec 2024 | $40.9M |
| FY Dec 2023 | $517.2M |
| FY Dec 2022 | $765.6M |
| FY Dec 2021 | $1.5B |
| Jun 2026 | $9.2M |
| Mar 2026 | $2.4M |
| Dec 2025 | $20.3M |
| Sep 2025 | $46.3M |
| Jun 2025 | $55.4M |
| Mar 2025 | $52.0M |
| Dec 2024 | $40.9M |
| Sep 2024 | $67.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-50.6%
TTM free cash flow over market value at close 2026-10-23
FCF yield SER
| FY Dec 2025 | -88.3% |
| FY Dec 2024 | -38.5% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -0.8% |
| FY Dec 2021 | -0.5% |
| Jun 2026 | -72.9% |
| Mar 2026 | -76.5% |
| Dec 2025 | -88.3% |
| Sep 2025 | -30.2% |
| Jun 2025 | -25.5% |
| Mar 2025 | -35.3% |
| Dec 2024 | -38.5% |
| Sep 2024 | -21.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SER
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $130.0K | $56.0K | $3.2M | $34.0K |
| Gross profit | n/a | n/a | $102.0K | $21.0K |
| Operating income | -$24.0M | -$17.0M | -$3.1M | -$7.0M |
| Net income | -$19.2M | -$11.1M | $5.3M | -$10.5M |
| EPS (diluted) | -1.91 | -1.51 | 0.73 | -9.70 |
| Operating cash flow | -$18.0M | -$17.1M | -$2.5M | -$5.9M |
| Cash | $3.1M | $3.7M | $7.6M | $645.0K |
| Long-term debt | $2.9M | $0 | $3.0M | $18.1M |
SEC XBRL, fiscal years, as known on 2026-10-27
SER Stock Sonar score 6/7 axes
Find similar shapesCompareSER ranks highest on growth (87th percentile) and risk and compliance (86th), and lowest on institutional and government (18th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SER filings, in plain words
Are Serina Therapeutics insiders buying or selling SER?
In the 180 days to 2026-10-27, Serina Therapeutics insiders were net buyers, a net $78.0K across purchases and sales reported on Form 4, by 4 buyers.
Read the full summary
In the 180 days to 2026-10-27, Serina Therapeutics insiders were net buyers of SER, a net $78.0K across purchases and sales reported on Form 4 by 4 buyers. 4 insiders reported purchases in that window. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
